{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:03:41Z","timestamp":1790136221601,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jiac.2022.10.017","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T01:11:18Z","timestamp":1667092278000},"page":"186-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics of flomoxef in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients undergoing lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6107-7170","authenticated-orcid":false,"given":"Toshinori","family":"Hirano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ohge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3775-989X","authenticated-orcid":false,"given":"Shinnosuke","family":"Uegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Watadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-463X","authenticated-orcid":false,"given":"Norifumi","family":"Shigemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1651-0091","authenticated-orcid":false,"given":"Hiroki","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-4458","authenticated-orcid":false,"given":"Yuki","family":"Kaiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5339-6534","authenticated-orcid":false,"given":"Shinya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2022.10.017_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.meegid.2018.04.005","article-title":"Current epidemiology, genetic evolution and clinical impact of extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"61","author":"Chong","year":"2018","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jiac.2022.10.017_bib2","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/jac\/dkx146","article-title":"Global epidemiology of CTX-M \u03b2-lactamases: temporal and geographical shifts in genotype","volume":"72","author":"Bevan","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2022.10.017_bib3","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/cid\/ciy768","article-title":"Carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae and the risk of surgical site infection after colorectal surgery: a prospective cohort study","volume":"68","author":"Dubinsky-Pertzov","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.017_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of Infections caused by extended-spectrum-beta-lactamase-, ampc-, and carbapenemase-producing Enterobacteriaceae","volume":"31","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2022.10.017_bib5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.jiac.2022.10.017_bib6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.7164\/antibiotics.38.466","article-title":"Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotic","volume":"38","author":"Tsuji","year":"1985","journal-title":"J Antibiot"},{"key":"10.1016\/j.jiac.2022.10.017_bib7","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1007\/BF01645536","article-title":"The meaning of the development of flomoxef and clinical experience in Japan","volume":"19","author":"Ito","year":"1991","journal-title":"Infection"},{"key":"10.1016\/j.jiac.2022.10.017_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40272-021-00465-z","article-title":"Potential antibiotics for the treatment of neonatal sepsis caused by multidrug-resistant bacteria","volume":"23","author":"Darlow","year":"2021","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jiac.2022.10.017_bib9","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00595-010-4511-x","article-title":"Antimicrobial prophylaxis and colon preparation for colorectal surgery: results of a questionnaire survey of 721 certified institutions in Japan","volume":"41","author":"Kobayashi","year":"2011","journal-title":"Surg Today"},{"key":"10.1016\/j.jiac.2022.10.017_bib10","first-page":"41","article-title":"Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia","volume":"69","author":"Partina","year":"2016","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2022.10.017_bib11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4172\/2332-0877.1000378","article-title":"Antimicrobial activity of flomoxef against Enterobacteriaceae including extended spectrum beta-lactamases-producing strains isolated at Ramathibodi Hospital: a 1000-bed tertiary care hospital in Bangkok, Thailand","volume":"6","author":"Santanirand","year":"2018","journal-title":"J Infect Dis Ther"},{"key":"10.1016\/j.jiac.2022.10.017_bib12","first-page":"71","article-title":"Evaluation of antibacterial activities of flomoxef against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation","volume":"66","author":"Ito","year":"2013","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2022.10.017_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.diagmicrobio.2018.11.017","article-title":"In vitro activity of flomoxef against extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Korea","volume":"94","author":"Jung","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.017_bib14","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.00701-15","article-title":"Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-\u03b2-lactamase-producing Escherichia coli bacteremia","volume":"59","author":"Matsumura","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2022.10.017_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/IDR.S146923","article-title":"Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia","volume":"11","author":"Lee","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiac.2022.10.017_bib16","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ijantimicag.2015.07.020","volume":"46","author":"Lee","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2022.10.017_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10156-008-0598-Z","article-title":"Development of breakpoints of cephems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in the peritoneal fluid of patients","volume":"14","author":"Ikawa","year":"2008","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2022.10.017_bib18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jiac.2019.08.019","article-title":"Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment","volume":"26","author":"Nakamura","year":"2020","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2022.10.017_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ijantimicag.2017.03.025","article-title":"Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment","volume":"50","author":"Murao","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2022.10.017_bib20","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.surg.2021.10.013","article-title":"Association of serum and fat tissue antibiotic concentrations with surgical site infections in lower gastrointestinal surgery","volume":"171","author":"Takayama","year":"2022","journal-title":"Surgery"},{"key":"10.1016\/j.jiac.2022.10.017_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2146\/ajhp120568","article-title":"American society of health-system pharmacists; infectious disease society of America; surgical infection society; society for healthcare epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery","volume":"70","author":"Bratzler","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jiac.2022.10.017_bib22","first-page":"137","article-title":"Assays of 6315-S (flomoxef) and its metabolites in body fluids by high-performance liquid chromatography","volume":"35","author":"Konaka","year":"1987","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2022.10.017_bib23","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A pharmacokinetic analysis program (multi) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J Pharmacobio-Dyn"},{"key":"10.1016\/j.jiac.2022.10.017_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijantimicag.2013.08.016","article-title":"Application of pharmacokinetic\/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve-based approaches","volume":"43","author":"Barbour","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2022.10.017_bib25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jiac.2015.04.015","article-title":"Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics","volume":"21","author":"Kobayashi","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2022.10.017_bib26","article-title":"Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients","author":"Ikawa","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2022.10.017_bib27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2007.06.001","article-title":"Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients","volume":"30","author":"Ikawa","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2022.10.017_bib28","first-page":"494","article-title":"Phase-1 clinical study on 6315-S (Flomoxef)","volume":"35","author":"Yasunaga","year":"1987","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jiac.2022.10.017_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11095-020-02977-8","article-title":"Pharmacokinetics\/pharmacodynamics evaluation of flomoxef against extended-spectrum beta-lactamase-producing Escherichia coli in vitro and in vivo in a murine thigh infection model","volume":"38","author":"Tashiro","year":"2021","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.jiac.2022.10.017_bib30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/jac\/dkab468","article-title":"Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales","volume":"77","author":"Darlow","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2022.10.017_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.017_bib32","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jiac.2021.03.010","article-title":"Change in antimicrobial susceptibility of pathogens isolated from surgical site infections over the past decade in Japanese nation-wide surveillance study","volume":"27","author":"Ueda","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2022.10.017_bib33","first-page":"73","article-title":"[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2012]","volume":"67","author":"Yamaguchi","year":"2014","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2022.10.017_bib34","first-page":"339","article-title":"[Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents - special references to bacteria isolated between April 2011 and March 2012]","volume":"67","author":"Shinagawa","year":"2014","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2022.10.017_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.01.009","article-title":"Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review","volume":"47","author":"Alobaid","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2022.10.017_bib36","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s11695-016-2331-9","article-title":"Optimal cefazolin prophylactic dosing for bariatric surgery: no need for higher doses or intraoperative redosing","volume":"27","author":"Chen","year":"2017","journal-title":"Obes Surg"},{"key":"10.1016\/j.jiac.2022.10.017_bib37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jchromb.2016.07.032","article-title":"Quantification of cefazolin in serum and adipose tissue by ultra high performance liquid chromatography-Tandem mass spectrometry (UHPLC-MS\/MS): application to a pilot study of obese women undergoing cesarean delivery","volume":"1031","author":"Lillico","year":"2016","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.jiac.2022.10.017_bib38","first-page":"968","article-title":"Diffusion into human prostate and clinical evaluation of 6315-S (flomoxef) in urinary tract infection","volume":"35","author":"Hoshi","year":"1987","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2022.10.017_bib39","first-page":"22","article-title":"A clinical study on pulmonary tissue uptake of flomoxef","volume":"44","author":"Imaizumi","year":"1991","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2022.10.017_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02303-21","article-title":"Population pharmacokinetic-pharmacodynamic target attainment analysis of flomoxef in the serum and liver tissue of patients undergoing hepatic resection","volume":"66","author":"Komatsu","year":"2022","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22003002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22003002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:05:10Z","timestamp":1761159910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X22003002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1341321X22003002"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.10.017","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of flomoxef in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients undergoing lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}